Fibrocell Science (NASDAQ:FCSC) vs. Amneal Pharmaceuticals (NASDAQ:AMRX) Head-To-Head Analysis

Fibrocell Science (NASDAQ:FCSC) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Fibrocell Science and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fibrocell Science N/A 23.10% 10.56%
Amneal Pharmaceuticals -19.61% 23.17% 3.94%

Volatility and Risk

Fibrocell Science has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Insider & Institutional Ownership

36.7% of Fibrocell Science shares are held by institutional investors. Comparatively, 35.7% of Amneal Pharmaceuticals shares are held by institutional investors. 1.1% of Fibrocell Science shares are held by insiders. Comparatively, 25.9% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Fibrocell Science and Amneal Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fibrocell Science $350,000.00 83.66 -$10.28 million ($1.45) -2.07
Amneal Pharmaceuticals $1.86 billion 0.79 -$169.73 million $0.95 5.17

Fibrocell Science has higher earnings, but lower revenue than Amneal Pharmaceuticals. Fibrocell Science is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Fibrocell Science and Amneal Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fibrocell Science 0 2 0 0 2.00
Amneal Pharmaceuticals 2 6 4 0 2.17

Fibrocell Science presently has a consensus target price of $3.00, indicating a potential upside of 0.00%. Amneal Pharmaceuticals has a consensus target price of $6.30, indicating a potential upside of 28.31%. Given Amneal Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than Fibrocell Science.

Summary

Amneal Pharmaceuticals beats Fibrocell Science on 9 of the 14 factors compared between the two stocks.

About Fibrocell Science

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit